{"id":2234,"date":"2025-12-29T11:03:52","date_gmt":"2025-12-29T03:03:52","guid":{"rendered":"https:\/\/www.hanchorbio.com\/?post_type=news&p=2234"},"modified":"2026-01-09T11:04:49","modified_gmt":"2026-01-09T03:04:49","slug":"hanchorbio-2025-milestones","status":"publish","type":"news","link":"https:\/\/www.hanchorbio.com\/en\/news\/hanchorbio-2025-milestones\/","title":{"rendered":"HanchorBio 2025 Milestones"},"content":{"rendered":"

HanchorBio 2025 Milestones<\/span><\/h1>\n

Patient First, <\/strong>Data <\/strong>Driven.<\/strong><\/span><\/h4>\n

HanchorBio is a clinical-stage biotechnology company advancing differentiated immuno-oncology biologics through its proprietary FBDB\u2122 (F<\/strong>c<\/strong>-Based D<\/strong>esigner<\/strong> Biologics<\/strong>) platform<\/strong>. In 2025, the platform achieved meaningful validation across clinical development, global scientific recognition, intellectual property, and capital markets, marking its transition from platform build-out to clinical execution.<\/span><\/p>\n

FBDB\u2122 Platform Overview<\/strong><\/span><\/h3>\n

The FBDB\u2122 platform enables the rational design of multi-functional fusion proteins intended to address key limitations of existing immuno-oncology therapies. Platform strengths demonstrated in 2025:<\/span><\/p>\n

    \n
  • Rational multi-target engagement to improve therapeutic index in solid tumors<\/span><\/li>\n
  • A diversified pipeline spanning clinical and preclinical stages<\/span><\/li>\n
  • Platform scalability validated through clinical data, global conferences, peer-reviewed publication, IP grants, and a completed licensing transaction<\/span><\/li>\n<\/ul>\n

    Key Milestones in 2025<\/strong><\/span><\/h2>\n

    Clinical & R&D Progress<\/strong><\/span><\/h3>\n
      \n
    • HCB101 advanced into a Phase 1b\/2 clinical trial<\/strong><\/span>
      \n2L GC combo therapy demonstrated an 80% objective response rate (ORR)<\/strong>, significantly outperforming historical standard-of-care (26.5%)<\/span><\/li>\n
    • TFDA approvals obtained for HCB101 combination therapy<\/strong> (HNSCC, CRC)<\/span><\/li>\n
    • HCB301 entered Phase I clinical trial <\/strong>and completed safety evaluations for two dose cohorts with favorable tolerability<\/span><\/li>\n
    • HCB303 entered IND-enabling preparation stage<\/strong><\/span><\/li>\n
    • HCB206: Program expansion into auto-immune disease, broadening platform applicability beyond oncology<\/strong><\/span><\/li>\n<\/ul>\n

      Global Scientific Presence<\/strong><\/span><\/h3>\n
        \n
      • ASCO 2025<\/strong>: Presentation of preliminary clinical data for HCB101<\/span><\/li>\n
      • ASH 2025<\/strong>: First-in-human monotherapy results of HCB101<\/span><\/li>\n
      • ESMO Immuno-Oncology Congress<\/strong>: Selected for mini-oral presentation<\/span><\/li>\n
      • Journal of Hematology & Oncology (JHO)<\/strong>: Peer-reviewed publication (IF: 40.4)<\/span><\/li>\n
      • SITC 2025<\/strong>: <\/strong>Preclinical data presentation for HCB301<\/span><\/li>\n
      • CBA Annual Meeting: <\/strong>Invited participant; sole\u00a0innovative drug company from Taiwan<\/span><\/li>\n<\/ul>\n

        Awards & Recognition<\/strong><\/span><\/h3>\n
          \n
        • IMAPAC 2025 Taiwan Biopharma Excellence Award<\/strong><\/span><\/li>\n
        • Taiwan B<\/strong>IO Awards<\/strong> 2025 <\/strong>“Startup <\/strong>of the Year<\/strong><\/span><\/li>\n<\/ul>\n

          Business & Corporate Progress<\/strong><\/span><\/h3>\n
            \n
          • HCB101 licensing agreement executed<\/strong><\/span>\n
              \n
            • USD 10 million upfront payment<\/span><\/li>\n
            • Up to USD192 million in development and commercial milestones<\/span><\/li>\n<\/ul>\n<\/li>\n
            • Company listed on the Taiwan Emerging Stock Market<\/strong> (7827.TPEx)<\/strong> <\/span>\n
                \n
              • Application submitted for listing on the Taiwan Innovation Board (TIB), pending approval<\/span><\/li>\n<\/ul>\n<\/li>\n
              • U.S. patent granted for HCB101<\/strong><\/span><\/li>\n<\/ul>\n

                Key Leadership Appointment<\/strong><\/span><\/h3>\n
                  \n
                • Alvin Luk, PhD, MBA, CCRA, was appointed as Group President & Chief Medical Officer (CMO)<\/strong>, strengthening clinical strategy, global development execution, and platform-to-patient translation<\/span><\/li>\n<\/ul>\n

                  Summary<\/strong><\/span><\/h2>\n

                  2025 marks HanchorBio\u2019s evolution from platform establishment to clinical and commercial validation.<\/strong><\/span>
                  \nThe FBDB\u2122 platform has progressed beyond concept, demonstrating its ability to generate clinically relevant therapeutics supported by human data, regulatory momentum, and external partnerships.<\/span><\/p>\n

                  HanchorBio enters 2026 as a company with:<\/span><\/p>\n

                    \n
                  • Multiple clinical-stage assets<\/span><\/li>\n
                  • A validated biologics platform<\/span><\/li>\n
                  • Growing global visibility<\/span><\/li>\n
                  • Clear pathways toward value inflection<\/span><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"

                    HanchorBio 2025 Milestones Patient First, Data Driven. HanchorBio is a clinical-stage biotechnology company advancing differentiated immuno-oncology biologics through its proprietary FBDB\u2122 (Fc-Based Designer Biologics) platform. In 2025, the platform achieved meaningful validation across clinical development, global scientific recognition, intellectual property, and capital markets, marking its transition from platform build-out to clinical execution. FBDB\u2122 Platform Overview […]<\/p>\n","protected":false},"featured_media":0,"template":"","news-category":[],"class_list":["post-2234","news","type-news","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news\/2234","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:attachment":[{"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/media?parent=2234"}],"wp:term":[{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/www.hanchorbio.com\/en\/wp-json\/wp\/v2\/news-category?post=2234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}